Glioma,　in　which　a　malignant　tumor　cell　occurs　in　neural　mesenchymal　cells,　has　a　rapid　progression　and　poor　prognosis,　which　is　still　far　from　desirable　in　clinical　treatments.　We　developed　a　lab-on-a-chip　(LOC)　device　for　the　rapid　and　efficient　preparation　of　vitexin/indocyanine　green　(ICG)　liposomes.　Vitexin　could　be　released　from　liposome　to　kill　cancer　cell,　which　can　potentially　improve　the　glioma　therapeutic　effect　and　reduce　the　treatment　time　through　synergistic　photodynamic/photothermal　therapies　(PDT/PTT).　The　vitexin/ICG　liposome　was　fabricated　via　LOC　and　its　physicochemical　property　and　release　in　vitro　were　evaluated.　3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium　bromide　(MTT)　method　and　live/dead　staining　were　used　to　examine　the　enhanced　antitumor　effect　of　vitexin/ICG　liposome　in　cooperation　with　PDT/PTT,　while　the　related　mechanism　was　explored　by　flow　cytometry　and　western　blot.　The　results　were　as　follows:　(1)　The　prepared　vitexin/ICG　liposome　was　smaller　in　size,　homogenous　in　particle　size　distribution　with　significant　low　polydispersity　index　(PDI),　and　enhanced　cumulative　release　in　vitro.　(2)　We　found　that　the　formulated　liposome　presented　strong　cancer　cell　inhibition　and　suppression　of　its　migration　in　a　dose-dependent　manner.　(3)　Further　mechanistic　studies　showed　that　liposome　combined　with　near-infrared　irradiation　could　significantly　upregulate　levels　of　B　cell　lymphoma　2-associated　X　(Bax)　protein　and　decrease　B　cell　lymphoma　2　(Bcl-2)　at　protein　levels.　The　vitexin/ICG　liposomes　prepared　based　on　a　simple　LOC　platform　can　effectively　enhance　the　solubility　of　insoluble　drugs,　and　the　combined　effect　of　PTT/PDT　can　effectively　increase　their　antitumor　effect,　which　provides　a　simple　and　valid　method　for　the　clinical　translation　of　liposomes.